PROJECT SUMIVIARY (See instructions): SWG 5: The primary purpose of the Curative Therapies SWG is to accelerate work toward a cure for HIV, by linking local investigators of curative therapies for HIV to the UW/FHCRC CFAR. SWG 5 will leverage a large NIH investment in the Seattle-led consortium defeat HIV, one of three Martin Delaney collaboratories focused on the cure of HIV. We intend to facilitate use of CFAR resources, including the clinical, basic science, and developmental cores, to leverage efficiencies of scale, develop novel research questions, and collectively pursue additional NIH and foundation-sponsored resources for the study of curative therapies for HIV. A secondary purpose is to link Seattle investigators with outside leaders in the field, to develop local expertise as well as enhance areas of local strength. These activities will add value to the UW/FHCRC CFAR, US CFARs generally, and defeat HIV, by establishing an international center of excellence in the study of curative therapies for HIV. SWG 6: The Substance Abuse (SA) SWG will consist of over 30 UW investigators working in four research emphasis areas: Sexual Behavior-Substance Abuse Nexus, Substance Abusing HIV Positive Individuals, Prevention of HIV among Substance Abusing Individuals, HIV/STI Epidemiology among Substance Abusers.
The aims of the SWG 6 are: 1) develop synergy and collaboration among local HIV substance abuse researchers, and 2) seek funding for identified collaborative opportunities and encourage early career and minority investigators to pursue substance abuse and HIV/STI related research. The success of the SA SWG will be determined by publication of manuscripts or acceptance of abstracts, and/or submissions for grant funding by SA SWG members and other CFAR investigators. SWG 7: Coverage gaps with efficacious interventions underscore the importance of improving knowledge translation and implementation to achieve scale.
The aim of the Implementation Science SWG is to improve the speed, efficiency and quality of translation of scientific evidence on HIV/STI prevention and care into effective, large scale health programs. SWG 7 will leverage local and international multidisciplinary expertise to develop innovative models for implementing and scaling-up efficacious HIV/STI interventions, and apply rigorous methods to develop a base of evidence to guide scale-up. Specific activities include bimonthly IS meetings to develop novel research methods for IS, foster interdisciplinary collaboration, and coordinate responses to funding opportunities;annual IS symposia;fostering collaboration among CFAR cores and extra-CFAR institutions;and IS education, training and mentoring internationally and at the UW.
Our 3 proposed SWGs propose to promote collaborations and accelerate the pace of research in three areas: Curative Therapies for HIV, bringing together scientists with many different areas of expertise to help them work toward a cure for HIV;Substance Abuse and HIV/STI, addressing the challenges presented by the intersection of substance abuse and HIV infection;and Implementation Science, providing critical resources to improve the quality of research and maximize the impact of HIV interventions worldwide.
|Stekler, Joanne D; McKernan, Jennifer; Milne, Ross et al. (2015) Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 20:77-80|
|Mohanraj, Rani; Jeyaseelan, Visalakshi; Kumar, Shuba et al. (2015) Cultural adaptation of the Brief COPE for persons living with HIV/AIDS in southern India. AIDS Behav 19:341-51|
|Slyker, Jennifer A; Casper, Corey; Tapia, Kenneth et al. (2014) Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy. Clin Infect Dis 58:1333-7|
|Mackelprang, Romel D; Bigham, Abigail W; Celum, Connie et al. (2014) Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans. J Infect Dis 209:1623-7|
|Gantt, Soren; Cattamanchi, Ashok; Krantz, Elizabeth et al. (2014) Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol 60:127-32|
|Puttkammer, Nancy H; Zeliadt, Steven B; Balan, Jean Gabriel et al. (2014) Before and after the earthquake: a case study of attrition from the HIV antiretroviral therapy program in Haiti. Glob Health Action 7:24572|
|Gerdts, Sarah E; Wagenaar, Bradley H; Micek, Mark A et al. (2014) Linkage to HIV care and antiretroviral therapy by HIV testing service type in Central Mozambique: a retrospective cohort study. J Acquir Immune Defic Syndr 66:e37-44|
|Liu, Yi; Rao, Ushnal; McClure, Jan et al. (2014) Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds. PLoS One 9:e94240|
|Chung, Michael H; Beck, Ingrid A; Dross, Sandra et al. (2014) Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya. J Acquir Immune Defic Syndr 67:246-53|
|Pantalone, David W; Huh, David; Nelson, Kimberly M et al. (2014) Prospective predictors of unprotected anal intercourse among HIV-seropositive men who have sex with men initiating antiretroviral therapy. AIDS Behav 18:78-87|
Showing the most recent 10 out of 552 publications